Tesamorelin
Tesamorelin (Egrifta)
The only FDA-approved GHRH analog specifically for reducing excess abdominal fat in HIV-associated lipodystrophy.
Typical Cost
$600-1200/month
Status
Research
Peptide Profile
Tesamorelin
Mechanism of Action
Stimulates endogenous growth hormone release with high specificity for visceral fat reduction. Improves lipid profiles in lipodystrophy.
Common Dosages
subcutaneous
2mg
Daily · 3-6 months
Benefits
Reduces visceral fat
Improves body composition
FDA-approved indication
Preserves lean mass
Side Effects
Injection site reactions
Joint pain
Hyperglycemia risk
Key Research
Tesamorelin FDA approval
Significant visceral adipose tissue reduction in HIV patients
Regulatory Status
FDA-approved (Egrifta) for HIV-associated lipodystrophy. Prescription required.
Contraindications
- ⚠Active malignancy
- ⚠Diabetic retinopathy
- ⚠Pregnancy/breastfeeding
For GLP-1 users with visceral fat concerns, tesamorelin offers clinically-validated option alongside SeraVia.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.